Search
Umeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigationalCOPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than … [A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product.
Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedBecause of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction … As a pro-drug of estradiol, estradiol cypionate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalA significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. … Salsalate is a nonsteroidal anti-inflammatory agent for oral administration.
Hyaluronidase (human recombinant)
go.drugbank.com/drugs/DB06205ApprovedInvestigationalA purified preparation of the enzyme recombinant human hyaluronidase. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalIdraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. … As a result, Sanofi stopped the development of the drug.
Categories: Factor Xa InhibitorsEtacrynic acid
go.drugbank.com/drugs/DB00903ApprovedInvestigationalA compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. … This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
Landiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigational[A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity … [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November
Erlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalRecent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index